Multifocal motor neuropathy (MMN) is an immune-mediated disorder characterized by slowly progressive asymmetrical limb weakness. Immunoglobulins (IVIg) remains the primary, FDA-approved, means to treat the condition. Anecdotal evidence suggests that immunosuppressive drugs as adjunctive therapy may be beneficial. Safety and efficacy of mycophenolate mofetil (CellCept) as adjunctive therapy for MMN patients receiving IVIg maintenance treatment […]